Gilead Email Format

Biotechnology Research
10,001-25,000 employees
Foster City, CA, USA

Gilead is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines in virology, oncology, and other therapeutic areas worldwide.

Find contacts at Gilead

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@gilead.com

Company Overview

Industry
Biotechnology Research
Founded
1987
Headquarters
Foster City, CA, USA
Revenue
$25B-$50B
FUNDING Stage
Public
Key Executives
Daniel O'Day (Chairman and Chief Executive Officer, Gilead Sciences), Andrew Dickinson (Chief Financial Officer), Johanna Mercier (Chief Commercial & Corporate Affairs Officer)

Tech Stack

AWS

Cloud

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Gilead?

Gilead uses the first.last format, so Jane Smith would be jane.smith@gilead.com.

What are Gilead's three main therapeutic areas in 2026?

Gilead focuses its research and commercial pipeline across three therapeutic areas: Virology, Oncology, and Inflammation. Within Virology, HIV treatment and prevention remains a cornerstone, with lenacapavir being a key asset in 2026.

How does Gilead's Kite Pharma subsidiary approach cancer treatment?

Kite Pharma, Gilead's oncology subsidiary, specializes in CAR T-cell therapy, a personalized cancer treatment that engineers a patient's own immune cells to fight cancer. Kite has multiple cell therapy products and next-generation candidates in active development in 2026.

Which company did Gilead acquire in 2026 to strengthen its multiple myeloma cell therapy portfolio?

Gilead completed its acquisition of Arcellx in April 2026 for approximately $7.8 billion, adding anito-cel, a promising CAR T-cell therapy for multiple myeloma, to its oncology pipeline alongside Kite's existing cell therapy platform.

Can Clay help me find a verified Gilead contact email using their first.last format?

Yes, Clay can help you verify and enrich Gilead contact emails. Since Gilead uses the first.last@gilead.com format, Clay can confirm or build email addresses for specific Gilead contacts, making it easier to reach the right person in their 14,613-person organization.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles